NEW YORK (GenomeWeb News) – Montreal-based Caprion Proteomics has won a $12.9 million contract from the National Institute of Allergy and Infectious Diseases to research biomarkers for infectious diseases, the company said today.
Under the five-year contract, Caprion will act as one of two NIAID Clinical Proteomics Centers for Infectious Disease and Biodefense.
The company will use its CellCarta protein profiling technology to conduct large-scale applied proteomics projects on human clinical samples.
The studies Caprion will conduct will focus on discovering, qualifying, and verifying candidate biomarkers that can be used to detect, diagnose, and monitor responses to therapeutics and vaccines and disease susceptibility.
Caprion said this is its second biodefense contract from NIAID. The company is still working on a contract awarded in 2004 that is focused on identifying new immunotherapy targets, vaccines, and diagnostic candidates that are based on host and pathogen proteins that are involved in Brucella infections.
Under the agreement, Caprion will retain the rights to commercialize candidate biomarkers and diagnostic products it discovers under the project. Proteomics discoveries and validation results generated through the research will be made public through the Proteomics Research Program Administrative Center.